胰腺癌患者腹腔灌洗细胞学检查阳性，术后进行长期辅助化疗。
Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology.
作者信息
Ohgi Katsuhisa, Sugiura Teiichi, Okamura Yukiyasu, Ashida Ryo, Yamada Mihoko, Otsuka Shimpei, Todaka Akiko, Uesaka Katsuhiko
机构信息
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka, 411-8777, Japan.
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
出版信息
Langenbecks Arch Surg. 2023 Apr 27;408(1):165. doi: 10.1007/s00423-023-02906-4.
PURPOSE
The significance of resection for pancreatic cancer with positive peritoneal lavage cytology (CY +) remains controversial, and the lack of evidence concerning adjuvant chemotherapy (AC) in these patients remains an issue. The aim of the present study was to investigate the prognostic impacts of AC and its duration on the survival outcome in patients with CY + pancreatic cancer.
METHODS
A total of 482 patients with pancreatic cancer who underwent pancreatectomy between 2006 and 2017 were retrospectively analyzed. The overall survival (OS) was compared among the patients with CY + tumors according to the duration of AC.
RESULTS
Among the resected patients, 37 (7.7%) had CY + tumors: 13 received AC for > 6 months, 15 received AC for ≤ 6 months and 9 did not receive AC. The OS of 13 patients with resected CY + tumors who received AC for > 6 months was comparable to that of 445 patients with resected CY- tumors (median survival time 43.0 vs. 33.6 months, P = 0.791), and was significantly better than that of 15 patients with resected CY + tumors who received AC for ≤ 6 months (vs. 16.6 months, P = 0.017). The duration of AC (> 6 months) was an independent prognostic factor in patients with resected CY + tumors (hazard ratio 3.29, P = 0.005).
CONCLUSION
Long-term AC (> 6 months) may improve postoperative survival in pancreatic cancer patients with CY + tumors.
目的
对于腹膜灌洗细胞学检查阳性（CY +）的胰腺癌患者，手术切除的意义仍存在争议，且缺乏关于这些患者辅助化疗（AC）的证据仍是一个问题。本研究的目的是探讨AC及其疗程对CY +胰腺癌患者生存结局的预后影响。
方法
回顾性分析了2006年至2017年间共482例行胰腺切除术的胰腺癌患者。根据AC疗程，比较CY +肿瘤患者的总生存期（OS）。
结果
在接受手术切除的患者中，37例（7.7%）为CY +肿瘤：13例接受AC超过6个月，15例接受AC≤6个月，9例未接受AC。13例接受AC超过6个月的CY +肿瘤切除患者的OS与445例CY-肿瘤切除患者相当（中位生存时间43.0对33.6个月，P = 0.791），且显著优于15例接受AC≤6个月的CY +肿瘤切除患者（对16.6个月，P = 0.017）。AC疗程（>6个月）是CY +肿瘤切除患者的独立预后因素（风险比3.29，P = 0.005）。
结论
长期AC（>6个月）可能改善CY +肿瘤的胰腺癌患者术后生存。
Zotero 插件